23andMe Continuing GWAS into Disease Factors; Official 'Optimistic' Over FDA Talks | GenomeWeb

By Tony Fong

SAN FRANCISCO (GenomeWeb News) – Genetic testing firm 23andMe is continuing to leverage its database of patients using its tests to perform additional research, its senior director of research said Tuesday.

At the annual Burrill Personalized Medicine Meeting here, Joanna Mountain told audience members that the Mountain View, Calif., company is currently preparing studies in three areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.